DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Monday

DiaMedica Therapeutics (NASDAQ:DMAC) is projected to release its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:00 PM ET.

DiaMedica Therapeutics Stock Performance

Shares of DMAC opened at $7.28 on Friday. The company has a 50 day moving average price of $8.16 and a 200-day moving average price of $7.58. DiaMedica Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $10.42. The stock has a market capitalization of $379.12 million, a PE ratio of -10.25 and a beta of 1.09.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th. Wall Street Zen cut DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Institutional Investors Weigh In On DiaMedica Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its position in shares of DiaMedica Therapeutics by 14.5% in the third quarter. Rhumbline Advisers now owns 27,357 shares of the company’s stock worth $188,000 after acquiring an additional 3,463 shares during the period. BNP Paribas Financial Markets grew its position in shares of DiaMedica Therapeutics by 24.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company’s stock valued at $74,000 after acquiring an additional 3,709 shares during the period. Bank of America Corp DE grew its position in shares of DiaMedica Therapeutics by 44.2% during the 3rd quarter. Bank of America Corp DE now owns 12,249 shares of the company’s stock valued at $84,000 after acquiring an additional 3,752 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of DiaMedica Therapeutics in the 3rd quarter valued at about $27,000. Finally, Invesco Ltd. increased its stake in shares of DiaMedica Therapeutics by 29.9% in the 4th quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock valued at $148,000 after purchasing an additional 4,293 shares in the last quarter. 10.12% of the stock is owned by hedge funds and other institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.